SEATTLE--(BUSINESS WIRE)--March 16, 2006--Targeted Genetics Corporation (Nasdaq:TGEN), a developer of molecular therapies for the prevention and treatment of acquired and inherited diseases, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to amend the clinical protocol of its ongoing Phase I trial of tgAAC94 in patients with inflammatory arthritis. As amended, the protocol now includes a higher dose and increases the number of patients targeted for enrollment from 40 to 120. Under the amended protocol, the study is now designated a Phase I/II trial.
